Diabetics may use continuous glucose monitors (CGMs) to track their blood sugar levels around the clock. They’re quite valuable, giving information on how your blood sugar responds to insulin, food, exercise, and anything else that influences it.
Abbott Laboratories Inc. as well as Dexcom according to Vantage Market Research, are the industry leaders in the CGM market, which reached $5.1 billion in sales in 2021 and is predicted to reach $13.2 billion by 2028. Abbott’s FreeStyle Libre CGM systems earned $3.7 billion in sales last year, with 4 million customers worldwide.
Abbott has recently unveiled the FreeStyle Libre 3, their newest CGM. It includes a significant improvement. Whereas the previous systems were “flash” CGMs, which means you had to hold your reader or phone close to the sensor to get a reading, the new version sends data straight to your phone.
I tried it out for over a month. My key takeaways are as follows:
How it works
The insertion device is packaged in a tiny box and is rather compact. The Food and Drug Administration has only authorized the Libre 3 for use in the arm. The insertion was painless, and the sensor itself is small in comparison to other sensors I’ve used.
